Here are three notes, from Mr. Slavitt’s comments:
1. Mr. Slavitt noted that there isn’t “enough public information on the effectiveness of new drugs in the real world or about prices and rebate structures.”
2. He also stated that a common understanding of the drug pricing data does not exist, making it harder to sift through the various costs associated with medications, such as list prices, wholesale prices, average wholesale prices, rebates, supplemental rebates, etc.
3. Mr. Slavitt notes that increasing the transparency of drug pricing and value information is necessary to prevent reactions to misinformation.
Learn more about key strategies & technologies for efficient, cost-effective ASCs — Click here!
More articles on ASC issues:
66 statistics on ASC gross charges & net revenue per case
It’s all about trust – Joe Zasa’s insights into successful joint ventures
Where do RNs earn the most? 10 statistics
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.